Regulatory Focus™ > News Articles > 2020 > 3 > COVID-19 therapeutics tracker

COVID-19 therapeutics tracker

Posted 19 November 2021 | By Jeff Craven 

COVID-19 therapeutics tracker

More than a year into the pandemic, only a handful of repurposed therapeutics have been approved to treat COVID-19: dexamethasone in the UK and Japan; Avigan (favilavir) in China, Italy and Russia; Veklury (remdesivir) in the US, UK and Japan and Lagevrio (molnupiravir) in the UK.
Regulators around the world have allowed a handful of additional treatments to be used on an emergency-use basis including Eli Lilly and Company’s monoclonal antibodies bamlanivimab with etesevimab; Regeneron’s casirivimab and imdevimab; GlaxoSmithKline/Vir Biotechology's Xevudy (sotrovimab); Roche's Actemra; Celltrion's Regkirona; and convalescent plasma. 

This tracker will be updated biweekly with the latest in developments for treatment candidates who have advanced to at least Phase 1 study. If you notice an issue with this data or wish to submit an update, please email Regulatory Focus at
Updated 19 November with new information on molnupiravir, ixagevimab and cilgavimab, Regkirona, casirivimab/imdevimab, Paxlovid plus ritonavir, sotrovimab, AT-527, Zyesami, Kevzara, ensovibep, and abivertinib.




© 2021 Regulatory Affairs Professionals Society.

Regulatory Focus newsletters

All the biggest regulatory news and happenings.